Engineered type IV pilin of Clostridium difficile
AssigneeUniversity of Maryland, Baltimore
InventorMichael Donnenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.
Claims12
An immunogenic composition comprising an isolated polypeptide comprising i) a C. difficile type IV pilin or an antigenic fragment or variant thereof, and ii) an affinity tag sequence to facilitate purification, wherein the antigenic fragment or variant thereof comprises a polypeptide sequence that has at least 90% sequence identity to a polypeptide sequence selected from the group consisting of:
- a. amino acids 35-173 of SEQ ID NO:2;
- b. amino acids 35-173 of SEQ ID NO:6;
- c. amino acids 35-173 of SEQ ID NO:10;
- d. amino acids 35-171 of SEQ ID NO:14;
- e. amino acids 35-170 of SEQ ID NO:18;
- f. amino acids 34-119 of SEQ ID NO:22;
- g. amino acids 31-116 of SEQ ID NO:26;
- h. amino acids 32-164 of SEQ ID NO:30;
- i. amino acids 32-164 of SEQ ID NO:34;
- j. amino acids 32-162 of SEQ ID NO:38;
- k. amino acids 36-272 of SEQ ID NO:42;
- l. SEQ ID NO:2;
- m. SEQ ID NO:6;
- n. SEQ ID NO:10;
- o. SEQ ID NO:14;
- p. SEQ ID NO:18;
- q. SEQ ID NO:22;
- r. SEQ ID NO:26;
- s. SEQ ID NO:30;
- t. SEQ ID NO:34;
- and
- u. SEQ ID NO:38.
Dependencies are inferred from the claim text.